The effect of disease modifying therapies on fatigue in multiple sclerosis

•Fatigue is a symptom with a serious impact on patients’ quality of life.•Inclusion of fatigue as an RCT outcome is crucial to understand the impact of DMTs.•Limited RCTs of DMTs assessed fatigue as an outcome.•The reporting of PROs of DMT trials assessing fatigue is suboptimal.•Carefully considerat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis and related disorders Jg. 79; S. 105065
Hauptverfasser:	Cruz Rivera, Samantha, Aiyegbusi, Olalekan Lee, Piani Meier, Daniela, Dunne, Achille, Harlow, Danielle E, Henke, Christian, Kamudoni, Paul, Calvert, Melanie J
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Netherlands Elsevier B.V 01.11.2023
Schlagworte:	Disease-modifying therapies (DMTs) Fatigue Fatigue - drug therapy Fatigue - etiology Humans Multiple Sclerosis - complications Multiple Sclerosis - therapy Neurology Patient Reported Outcome Measures Patient-reported outcomes (PROs) Reference Standards Systematic Reviews as Topic Fatigue Patient-reported outcomes (PROs) Disease-modifying therapies (DMTs) patient-reported outcomes (PROs) fatigue disease-modifying therapies (DMTs)
ISSN:	2211-0348, 2211-0356, 2211-0356
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!